Table 2.
Infections during Gammaplex 5% therapy.
| Variable | Subjects (N = 25) |
|---|---|
| Subjects with SABIs, n (%) | 2 (8·0) |
| Subjects recording infection during study, n (%) | 21 (84·0) |
| Overall upper respiratory tract infection | 16 (64·0) |
| Sinus infection | 10 (40·0) |
| Lower respiratory tract infection | 7 (28·0) |
| Gastrointestinal infection | 4 (16·0) |
| Urinary tract infection | 1 (4·0) |
| Other infection* | 8 (32·0) |
| Infectious episodes per subject per year† | |
| Mean (s.d.) | 3·20 (2·7) |
| Median (range) | 3·08 (0–10·4) |
| Number of infectious episodes per subject per year, n (%)† | |
| None | 4 (16·0) |
| > 0 to < 3 | 7 (28·0) |
| 3 to < 5 | 9 (36·0) |
| 5 to < 10 | 4 (16·0) |
| ≥10 | 1 (4·0) |
*Other infections (recorded for ≤ 4 subjects each) included influenza, otitis media, herpes simplex, tonsillar disorder, staphylococcal infection and oral fungal infection.
†If the patient recorded a possible infection on his/her diary card for any day, an infection was presumed whether or not it was confirmed by a health‐care professional. Infections per subject per year were calculated as number of infections × 365/number of days in study. SABI = serious acute bacterial infection; s.d. = standard deviation.